-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For a long time, the dynamics of institutional research has attracted the attention of investors and the mark.
In the past 5 trading days (from May 19 to May 25), a total of over 130 companies in the two cities have obtained institutional research, of which 8 companies have obtained more than 100 research institutions, and 2 are pharmaceutical compani.
Specifically, Boya Bio has attracted a lot of attenti.
The company has obtained 2 institutional surveys in the past 5 trading days, and the number of institutions participating in the survey has reached 200, which can be said to have earned enough attenti.
Among them, on May 24, 2022, Boya Bio received a total of 34 institutional surveys, including 13 fund management companies, 7 securities companies, 7 investment companies, and 4 asset management compani.
In the interactive session, the agency mainly paid attention to the company's future strategic planning, the company's pulp mining planning and main measures during the 14th Five-Year Plan period, the impact of the epidemic on pulp mining, the current status of Danxia Biotechnology and the next ste.
Among them, in response to planning issues, the company said that in the future, it will further focus on the main business of blood produc.
The main strategic measures are: in terms of pulp station and pulp volume, strive to double during the 14th Five-Year Plan period; in terms of product research and development, continue to develop new products and improve product pipelin.
During the 14th Five-Year Plan period, we will strive to achieve the approval of a new product for the market every year; in terms of marketing, we will continue to promote the academic promotion of new products to enhance the recognition of the company's products in the terminal market; in terms of production capacity assurance, we will accelerate the promotion of smart factories (Phase I) Engineering constructi.
According to the data, Boya Bio is a pharmaceutical manufacturing enterprise, mainly engaged in the development, production and sales of blood produc.
The 2021 annual report shows that in 2021, the company will achieve a total operating income of 651 billion yuan, a year-on-year increase of 47%; net profit attributable to the parent is 345 million yuan, a year-on-year increase of 34
In the first quarter of 2022, the company achieved a total operating income of 655 million yuan, a year-on-year increase of 89%; net profit attributable to the parent was 104 million yuan, a year-on-year increase of 8
In addition, Tonghe Pharmaceutical has also received extensive attention from institutions recently, with a total of 100 institutions in 5 trading da.
The key institutions participating in the research include China Universal Fund, Harvest Fund, Invesco Great Wall, E Fund,e.
During the research activities, the agency paid more attention to the possibility of the company's API industry returning overseas (the United States, India, e.
In response, the company replied that it is unlikely to return in the short term, and it may take 10 to 20 yea.
Return secti.
There are three main reasons: First, there are currently most of the chemists and engineers in China; There are a large number of industrial workers, and labor costs are low.
"China's quality management of APIs has also been on par with the US FDA, and it will be difficult for the API industry to return to the United States for a long ti.
In addition to lower environmental protection costs, the API industry in India has a lot of advantages in synthesis technology, production equipment, Quality management is not as good as China, and we believe that it is unsustainable to not pay attention to the development of environmental protection, in contrast, the prospects of China's API industry are bett.
" According to the data, Tonghe Pharmaceutical is a characteristic API manufacturer in Chi.
The production capacity and product quality of major varieties are at a high level in Chi.
The 2021 annual report shows that the company achieved revenue of 592 million yuan, a year-on-year increase of 399%; net profit attributable to the parent was 81 million yuan, a year-on-year increase of 18
In addition, according to the company's 2022 first quarter report, the main income was 180 million yuan, a year-on-year increase of 389%; the net profit attributable to the parent was 28282 million yuan, a year-on-year increase of 32
Click to enter the exhibition page
In the past 5 trading days (from May 19 to May 25), a total of over 130 companies in the two cities have obtained institutional research, of which 8 companies have obtained more than 100 research institutions, and 2 are pharmaceutical compani.
Specifically, Boya Bio has attracted a lot of attenti.
The company has obtained 2 institutional surveys in the past 5 trading days, and the number of institutions participating in the survey has reached 200, which can be said to have earned enough attenti.
Among them, on May 24, 2022, Boya Bio received a total of 34 institutional surveys, including 13 fund management companies, 7 securities companies, 7 investment companies, and 4 asset management compani.
In the interactive session, the agency mainly paid attention to the company's future strategic planning, the company's pulp mining planning and main measures during the 14th Five-Year Plan period, the impact of the epidemic on pulp mining, the current status of Danxia Biotechnology and the next ste.
Among them, in response to planning issues, the company said that in the future, it will further focus on the main business of blood produc.
The main strategic measures are: in terms of pulp station and pulp volume, strive to double during the 14th Five-Year Plan period; in terms of product research and development, continue to develop new products and improve product pipelin.
During the 14th Five-Year Plan period, we will strive to achieve the approval of a new product for the market every year; in terms of marketing, we will continue to promote the academic promotion of new products to enhance the recognition of the company's products in the terminal market; in terms of production capacity assurance, we will accelerate the promotion of smart factories (Phase I) Engineering constructi.
According to the data, Boya Bio is a pharmaceutical manufacturing enterprise, mainly engaged in the development, production and sales of blood produc.
The 2021 annual report shows that in 2021, the company will achieve a total operating income of 651 billion yuan, a year-on-year increase of 47%; net profit attributable to the parent is 345 million yuan, a year-on-year increase of 34
In the first quarter of 2022, the company achieved a total operating income of 655 million yuan, a year-on-year increase of 89%; net profit attributable to the parent was 104 million yuan, a year-on-year increase of 8
In addition, Tonghe Pharmaceutical has also received extensive attention from institutions recently, with a total of 100 institutions in 5 trading da.
The key institutions participating in the research include China Universal Fund, Harvest Fund, Invesco Great Wall, E Fund,e.
During the research activities, the agency paid more attention to the possibility of the company's API industry returning overseas (the United States, India, e.
In response, the company replied that it is unlikely to return in the short term, and it may take 10 to 20 yea.
Return secti.
There are three main reasons: First, there are currently most of the chemists and engineers in China; There are a large number of industrial workers, and labor costs are low.
"China's quality management of APIs has also been on par with the US FDA, and it will be difficult for the API industry to return to the United States for a long ti.
In addition to lower environmental protection costs, the API industry in India has a lot of advantages in synthesis technology, production equipment, Quality management is not as good as China, and we believe that it is unsustainable to not pay attention to the development of environmental protection, in contrast, the prospects of China's API industry are bett.
" According to the data, Tonghe Pharmaceutical is a characteristic API manufacturer in Chi.
The production capacity and product quality of major varieties are at a high level in Chi.
The 2021 annual report shows that the company achieved revenue of 592 million yuan, a year-on-year increase of 399%; net profit attributable to the parent was 81 million yuan, a year-on-year increase of 18
In addition, according to the company's 2022 first quarter report, the main income was 180 million yuan, a year-on-year increase of 389%; the net profit attributable to the parent was 28282 million yuan, a year-on-year increase of 32
Click to enter the exhibition page
